LONDON, April 24, 2013 /PRNewswire/ --
GlaxoSmithKline reported a 2% decline in Group revenues in line
with expectations and a dividend increase of 6% as part of its 2013
Q1 results. The pharmaceutical giant also officially announced the
divestment of Lucozade and Ribena as well as the creation of a
'Global Established Products' group within its portfolio that would
get a different strategic focus from the more innovative
products.
In a video interview, Chief Financial Officer Simon Dingemans said he felt "very comfortable"
about the trends the group was seeing from its performance with
strong results from Japan and the
US offsetting the tougher European environment.
He emphasized his confidence that the Group was on track to
deliver the guidance of 3 to 4% earnings growth in constant
currency terms, on sales growth of around 1%. He also highlighted
the "significant, continued progress" GSK was making in the
pipeline with six new products that had been "called out in front
of regulators on both sides of the Atlantic".
The video interview and transcript are available to watch now
for free at http://video.merchantcantos.com.
MerchantCantos produces in-depth interviews, documentaries and
webcasts with senior company executives. If you would like to
contact us, please email prnsupport@merchantcantos.com or phone
+44-207-936-1352.